Pfizer Inc. (NYSE:PFE) Holdings Decreased by Intrust Bank NA

Intrust Bank NA reduced its holdings in Pfizer Inc. (NYSE:PFE) by 9.7% in the 4th quarter, Holdings Channel reports. The fund owned 54,341 shares of the biopharmaceutical company’s stock after selling 5,805 shares during the period. Intrust Bank NA’s holdings in Pfizer were worth $1,564,000 as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of PFE. Bfsg LLC increased its stake in shares of Pfizer by 5.9% in the third quarter. Bfsg LLC now owns 168,804 shares of the biopharmaceutical company’s stock worth $5,599,000 after acquiring an additional 9,442 shares during the last quarter. Schmidt P J Investment Management Inc. increased its position in Pfizer by 7.0% in the 3rd quarter. Schmidt P J Investment Management Inc. now owns 10,286 shares of the biopharmaceutical company’s stock worth $321,000 after purchasing an additional 677 shares during the last quarter. Ascent Wealth Partners LLC raised its stake in shares of Pfizer by 2.5% during the 3rd quarter. Ascent Wealth Partners LLC now owns 42,699 shares of the biopharmaceutical company’s stock worth $1,416,000 after purchasing an additional 1,040 shares in the last quarter. Avestar Capital LLC lifted its holdings in shares of Pfizer by 3.7% during the 3rd quarter. Avestar Capital LLC now owns 17,160 shares of the biopharmaceutical company’s stock valued at $569,000 after buying an additional 606 shares during the last quarter. Finally, Lake Street Financial LLC grew its stake in shares of Pfizer by 22.3% in the 3rd quarter. Lake Street Financial LLC now owns 55,021 shares of the biopharmaceutical company’s stock valued at $1,766,000 after buying an additional 10,047 shares in the last quarter. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities analysts have commented on the stock. TD Cowen downgraded shares of Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 target price on the stock. in a research report on Thursday, January 4th. Guggenheim initiated coverage on Pfizer in a research report on Friday, February 23rd. They set a “buy” rating and a $36.00 target price for the company. Argus lowered shares of Pfizer from a “buy” rating to a “hold” rating in a research report on Friday, March 22nd. Finally, Cantor Fitzgerald reiterated an “overweight” rating and issued a $45.00 target price on shares of Pfizer in a report on Monday, April 15th. Eleven analysts have rated the stock with a hold rating and six have issued a buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $36.33.

Pfizer Price Performance

Shares of PFE stock traded up $0.02 during mid-day trading on Tuesday, reaching $25.66. The company’s stock had a trading volume of 4,742,252 shares, compared to its average volume of 41,542,797. The firm’s 50-day moving average is $26.92 and its two-hundred day moving average is $28.31. The company has a market cap of $145.30 billion, a P/E ratio of 71.25, a PEG ratio of 1.14 and a beta of 0.61. Pfizer Inc. has a 1-year low of $25.20 and a 1-year high of $40.37. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.69 and a current ratio of 0.91.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.10 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.29. Pfizer had a return on equity of 10.88% and a net margin of 3.62%. The firm had revenue of $14.25 billion for the quarter, compared to analysts’ expectations of $14.37 billion. During the same period in the prior year, the business posted $1.14 earnings per share. The business’s revenue was down 41.3% compared to the same quarter last year. On average, research analysts predict that Pfizer Inc. will post 2.24 earnings per share for the current year.

Pfizer Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, June 14th. Stockholders of record on Friday, May 10th will be paid a $0.42 dividend. This represents a $1.68 dividend on an annualized basis and a dividend yield of 6.55%. The ex-dividend date of this dividend is Thursday, May 9th. Pfizer’s dividend payout ratio (DPR) is currently 466.67%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.